Skip to content
drillr.ai

ESPR

Esperion Therapeutics, Inc.

NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.18+0.00%

Price as of Jul 14, 2026

ESPR news

Esperion Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

    Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54556110&newsitemid=20260617386094&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=87987f6cc1a3f2c6dc3afac6d641c1f9) , LLC (“KSF”) are i

    Business Wire ·

  2. Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  3. SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH

    SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH PR Newswire NEW YORK, May 6, 2026 NEW YORK, May 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4682320-1&h=1175794905&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde) with Monteverde & Associates PC (https://edge.prne

    PR Newswire ·

  4. Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Halper

    Globe Newswire ·

  5. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - SKYT)

    BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Esperion Therapeutics, Inc. (Nasdaq – ESPR) Under the terms of the Merger Agreement, Esperion will be acquired by funds managed by ARCHIMED for $3.16 per share i

    Globe Newswire ·

  6. $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC

    NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=hWLh-bzWB_F6QWJ1UbDcmAsy_YIAW4Z_rwKoMylV_L40lBKO-E799h3wDP5tXLYvxXw8ODfGaMuNrdhR8ubuWmDBdlHNk6xuLP_fhvVKqfVdw76wEsIm66_3qXJVV8i439zXyFsHy9O_E3T2ved1OggkGlEZDkJQOUgJYe2xOMt-64UxdHRsSOKWeHi-eN7e748jadCex_TCrkDtR2issA==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=UtwM8K3EueY64W2BI_i7eLBwQelXMjy2FzLkkcrDSqjSbn8aJWVaOZJ8ulsS8u53pLb2B_J0tit4ESC3p

    Globe Newswire ·

  7. Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders?

    Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible f

    PR Newswire ·

  8. $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)

    NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde (https://www.globenewswire.com/Tracker?data=QSMy3LL9BbaknnOeKC4U7LPAYxBLlY1RFaIx79TUpGnRb7LKAvuH5raF1AeBw0DHhvErUAQlyLP812VwQFZxeB94P4j4l7_7NnHJSX5f8mw1oxjq-Si48ftZGKXExrgu-dP2yiZtCtuLhYTRaTv9szrBhHIlftzQkB_dFWLWh7GfrpFGVQIJTkNlK_kWY3Pd3SkuHfLVTWo-HyDDXdk-OQ==) with Monteverde & Associates PC (https://www.globenewswire.com/Tracker?data=Di2ijPu_Zl8fqhj2QC2QHX_xNQDvpLw71cYsC7MbURrRWP0LCaadNK_dYKHja89POm3u5YDAI8STprE1

    Globe Newswire ·

  9. Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

    Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, May 1, 2026 MILWAUKEE, May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with ARCHIMED. (https://mma.prnewswire.com/media/2672539/Ademi_Fruchter__Logo.html) Click here (https://edge.prnewswire.com/c/link/?t=0&

    PR Newswire ·

  10. ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

    ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby yo

    Business Wire ·

  11. Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

    * Athyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka’s bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 million * Athyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to Esperion * Financing supports Esperion’s acquisition of Corstasis Ther

    Globe Newswire ·

  12. Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion’s Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the tr

    Globe Newswire ·

  13. Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

    ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25(th) Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website (https://www.globenewswire.com/Tracker?data=GaO30AXSj9IdOlCUO-PI68rDIyGIIjQy2iCU0YhB_mT6rK7r_LQq80dRlyo7_6eWwgJVVTgUaE8LNApq-VT7vroNeAyqXrW9qnVwgeS-ap2bqB1t7IUH7_WhsvCodRYe

    Globe Newswire ·

  14. Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

    – Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Lo

    Globe Newswire ·

  15. Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. E

    Globe Newswire ·

  16. Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to

    Globe Newswire ·